Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Nicox Extends Cash Runway into Q4 2025
Press ReleaseNicox Extends Cash Runway into Q4 2025 Flexible equity financing line with Vester Finance of up to 10,000,000 shares over 24 monthsImmediate upfront payment from Vester Finance of €0.5 million extends the cash runway into Q4 2025, enabling focus on future growthOngoing discussions and business development outreach underway for NCX 470 U.S. partnershipTwo NCX 470 clinical readouts in 2025 – Whistler Mechanism of Action in Q2...
Nasdaq GlobeNewswire
06/03/2025
Fagron publishes its annual report 2024
Regulated information – inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2025 – 7AM CET Fagron publishes its annual report 2024Fagron, the leading global player in pharmaceutical compounding, today publishes its annual report 2024. Discussion of the annual report and the approval of the financial statements will be put on the agenda of the annual general meeting of shareholders scheduled for 12 May 2025.The annual report is available in the official Dutch...
Nasdaq GlobeNewswire
06/03/2025
HKIAAC - At the forefront of the international anti-corruption cause
Officers from the HKIAAC also travelled worldwide to provide customized trainings on capacity building, reaching out to places far and wide, including Mali, Kazakhstan, Greece, Panama, Mongolia, South Africa, Brunei and Abu Dhabi. Officers from the HKIAAC also travelled worldwide to provide customized trainings on capacity building, reaching out to places far and wide, includingMali,Kazakhstan,Greece,Panama,Mongolia,South Africa,Bruneiand Abu Dhabi. Locally inHong...
PR Newswire
06/03/2025
Global Biosensors Market to Show Positive Growth at a CAGR of ~8% by 2032 |…
Key Takeaways from the Biosensors Market Report Key Takeaways from the Biosensors Market Report To read more about the latest highlights related to the biosensors market, get a snapshot of the key highlights entailed in theGlobal Biosensors Market Report Biosensors Overview Biosensors are analytical devices that combine a biological element, such as enzymes, antibodies, or nucleic acids, with a physicochemical detector to measure the presence of specific substances...
PR Newswire
06/03/2025
Global Interferons Market is Predicted to Reach ~USD 14 Billion by 2032 |…
Key Takeaways from the Interferons Market Report Key Takeaways from the Interferons Market Report To read more about the latest highlights related to the interferons market, get a snapshot of the key highlights entailed in theGlobal Interferons Market Report Interferons Overview Interferons (IFNs) are a group of signaling proteins that play a critical role in the immune response, particularly in defending against viral infections and modulating the activity of immune cells...
PR Newswire
05/03/2025
XPOVIO Continues to Disrupt the Oncology Market with Expanded Indications and…
Karyopharm Therapeutics' XPOVIO (selinexor) Overview Karyopharm Therapeutics' XPOVIO (selinexor) Overview XPOVIO is a pioneering oral inhibitor of Exportin-1 (XPO1) and the first in Karyopharm's Selective Inhibitor of Nuclear Export (SINE) class for cancer treatment. It works by selectively binding to and blocking the nuclear export protein XPO1. In preclinical studies, selinexor reversibly inhibits the nuclear export of Tumor Suppressor Proteins (TSPs), growth regulators, and...
PR Newswire
05/03/2025
Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual
Q1 Investor Summit VirtualFormat: Presentation Presenter: Steve Shallcross, CEO and Manel Cascallo, PhD., General Director Presentation Date and Time: Tuesday, March 11, 2025, 12:30 PM ET Webcast: ClickHereAbout Theriva™ Biologics, Inc. Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform...
Nasdaq GlobeNewswire
05/03/2025
NTG Nordic Transport Group Annual Report for 2024
Company announcement no. 2 – 2505 March 2025 NTG Nordic Transport Group Annual Report for 2024 NTG Nordic Transport Group A/S (“NTG”) has today published the 2024 Annual Report. Selected financial highlights are presented below: Full year Q4(DKKm) 2024 2023 20242023 Net revenue 9,3528,338 2,5932,001Gross profit 1,9731,866 579463Operating profit before special items (adj. EBIT) 524630 131171...
Nasdaq GlobeNewswire
05/03/2025
Press release: Sanofi successfully prices EUR 1.5 billion of bond issue
Sanofi successfully prices EUR 1.5 billion of bond issue Paris, March 5, 2025.Sanofi announces that it has successfully priced its offering of EUR 1.5 billion of notes across 2 tranches: €850 million floating rate notes, due March 2027, bearing interest at 3-month Euribor plus 0.300%€650 million fixed rate notes, due March 2031, bearing interest at an annual rate of 2.750%. The notes are being issued off the company's Euro Medium Term Note Program. Sanofi intends to use the net...
Nasdaq GlobeNewswire
05/03/2025
VALNEVA Declaration of shares and voting rights: February 28, 2025
VALNEVADeclaration of shares and voting rightsFebruary 28, 2025__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: March 5, 2025 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights* Description of the...
Nasdaq GlobeNewswire
05/03/2025
Handicrafts Market to Reach USD 2317183.92 million by 2030, Growing at an 11.00%…
Browse the report and understand how it can benefit your business strategy – https://www.credenceresearch.com/report/handicrafts-market Browse the report and understand how it can benefit your business strategy –https://www.credenceresearch.com/report/handicrafts-market Key Growth Determinants Rising Global Demand for Ethnic and Traditional Products: The handicrafts market is buoyed significantly by a surge in global demand for ethnic and traditional products. This trend is...
PR Newswire
05/03/2025
HEOR Services Market Size Booms with CAGR 12.3%, Projected to Reach $3.79…
HEOR Services Market Overview of Report Findings HEOR Services Market Overview of Report Findings For Detailed HEOR Services Market Insights, Visit: https://www.theinsightpartners.com/reports/health-economics-and-outcomes-research-heor-services-market Competitive Strategy and Development Global Headlines on HEOR services Stay Updated on The Latest HEOR Services Market Trends: https://www.theinsightpartners.com/sample/TIPRE00017816/ Market...
PR Newswire
05/03/2025
Fusion Biopsy Market is expected to generate a revenue of USD 1448.15 Million by…
The Fusion Biopsy Market is witnessing rapid growth, driven by increasing adoption of precision diagnostic techniques for prostate cancer and other malignancies. Fusion biopsy, which combines MRI and ultrasound imaging, has emerged as a game-changer in early cancer detection and treatment planning. The report delves into market dynamics, including technological advancements, regulatory updates, and competitive strategies shaping the industry. The Fusion Biopsy Market is witnessing rapid…
PR Newswire
05/03/2025
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…
ORION CORPORATIONSTOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 5 March 2025 at 17.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 4 March 2025...
Nasdaq GlobeNewswire
05/03/2025
Digital X-ray Market is expected to generate a revenue of USD 7.56 Billion by…
The Digital X-ray Market is experiencing significant growth, driven by increasing demand for advanced diagnostic imaging, rising healthcare investments, and continuous technological innovations such as artificial intelligence (AI)-assisted imaging and portable X-ray solutions. The report explores how digital X-ray systems are replacing traditional analog methods, improving diagnostic accuracy, and streamlining workflow efficiency across hospitals, clinics, and diagnostic centers worldwide…
PR Newswire
05/03/2025
Laminar Pharma Announces first open-label Progression-Free Survival data for…
Although the main primary outcome of the interim analysis (Hazard Ratio of 0.5 for PFS) was not reached for the whole trial population, the unblinding of the trial has allowed Laminar to conduct an ongoing evaluation (non-statistically assessed and with data under monitoring review) considering the per protocol predefined stratification: methylation status of the MGMT promoter and RTOG score (3, 4 or 5), a scale describing the side effects caused by radiation therapy and the higher the RTOG…
PR Newswire
05/03/2025
Ascend Advanced Therapies Appoints John Chiminski as Chair and Karen Flynn as…
John Chiminskibrings more than three decades of leadership in healthcare and pharma services. He served as CEO of Catalent from 2009 to 2015, then as Chair and CEO from 2016 through 2022, and as Executive Chair untilJune 2023. Under his leadership, Catalent grew into a global Tier 1 CDMO, expanded its capabilities, and significantly increased its impact on the pharma and biotech development and manufacturing ecosystem. He currently serves as a board member for QuidelOrtho (QDEL)...
PR Newswire
05/03/2025
EMFACE Surpasses 1 Million Treatments, Becoming the Fastest-Growing Non-Invasive…
"The ability to stimulate elevator muscles allows us to lift facial features from within—something that was never possible before with injectables or traditional energy-based devices," said Dr. Yael Halaas, a facial plastic surgeon from NYC, USA. " The ability to stimulate elevator muscles allows us to lift facial features from within—something that was never possible before with injectables or traditional energy-based devices," said Dr.Yael Halaas, a facial plastic surgeon…
PR Newswire
05/03/2025
Pow.Bio Unveils State-of-the-Art Facility in Alameda, Expanding Biomanufacturing…
Pow.Bio , a leader in innovative biomanufacturing solutions, is pleased to announce the opening of its new cutting-edge facility in Alameda, California.The new 25,000 sq ft facility, located at Marina Village in Alameda, boasts state-of-the-art production facilities equipped with AI-enabled continuous fermentation capabilities, enabling partners to achieve target production costs for competitive manufacturing:Continuous Fermentation System : The facility houses a fleet of dual-chamber...
Nasdaq GlobeNewswire
05/03/2025
Election of employee representatives to the Board of Directors
The employees have conducted the election of employee representatives to the Board of Directors of Novonesis (Novozymes A/S). The following employee representatives (in alphabetical order after surname) were elected for the next four years: Robert Nøddeskov Jensen, Senior Operator - newly electedLars Bo Køppler, Technician - newly electedPreben Nielsen, Science Manager – re-electedFrederikke Rose Spenner, Production Engineer - newly elected As alternates to the employee...
Nasdaq GlobeNewswire
05/03/2025
Tecan schedules conference call on March 12 to discuss Full-Year 2024 Financial…
Tecan schedules conference call on March 12 to discuss Full-Year 2024 Financial Results Männedorf, Switzerland, March 5, 2025– The Tecan Group (SIX Swiss Exchange: TECN) will hold an Analyst and Media conference call to discuss the full-year 2024 financial results on Wednesday, March 12, 2025 at 09:00 am CET. The press release with the 2024 full-year financial results and the Annual Report 2024 will be published on March 12, 2025 at 6:00 am CET. The conference call will be audio-webcast...
Nasdaq GlobeNewswire
05/03/2025
SKF launches updated brand to increase stakeholder value
"Our brand is the accumulation of everything we do – innovations, values, people, reputation, communication and our desired future state. From a business perspective, we are building favorability among current and potential customers, employees, investors, partners, and beyond. It is a way of earning our place in the world while staying true to our values and purpose," says Rickard Gustafson, President and CEO. "Our brand is the accumulation of everything we do – innovations…
PR Newswire
05/03/2025
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides…
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Completed enrollment of second dose cohort of EOS-984 + pembrolizumab combination in ongoing Phase 1 trial - EOS-215 Phase 1 trial TRM-010 patient enrollment anticipated to begin in 2Q25 - Cash balance and investment balance of $655.0 million as of December 31, 2024 expected to provide runway...
Nasdaq GlobeNewswire
05/03/2025
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology…
-Transaction represents total cash consideration of approximately $935 million, or $8.55 per share- -Transaction represents total cash consideration of approximately$935 m illion, or$8.55per share- DUBLINandDURHAM, N.C. , March 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") and Chimerix (Nasdaq: CMRX) ("Chimerix"), today announced the companies have entered into a definitive agreement for Jazz to acquire Chimerix for$8...
PR Newswire
05/03/2025
Altri Comunicati
